Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexis Stamatikos has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Utilizing Liposomes That Selectively Target Inflamed Endothelium to Upregulate Macrophage-Like Cell ABCA1 Through Endothelial Cell-Derived Exosome-Mediated Processes

    by Saphala Dhital, Jing Echesabal-Chen, Achala Pokhrel, Ally Brawner, Kun Huang, Rhonda R. Powell, Terri Bruce, Lucia Vojtech, Hanjoong Jo, Alexis Stamatikos

    Background: Atherosclerosis is caused by lipid accumulation in arterial endothelial cells and intimal cells. Atherosclerosis generally occurs in arteries that exhibit vascular inflammation, thereby making pro-inflammatory arterial endothelial cells a potential target for delivering atheroprotective material. Lipid-laden macrophages and vascular smooth muscle cells that have transdifferentiated into macrophage-like cells from cholesterol accumulation are the two primary intimal cell types that drive atherosclerosis. We have constructed a novel liposome-based therapeutic system (LP-pXMoA5p) that can specifically target inflamed arterial endothelial cells, resulting in endothelial cells that internalize LP-pXMoA5p to express and then package anti-miR-33a-5p into exosomes that are released basolaterally, which may lead to effective transfer of atheroprotective anti-miR-33a-5p to intimal cells. We have previously tested this delivery method with cultured macrophages being the recipient of endothelial-cell-derived exosomes filled with anti-miR-33a-5p, resulting in enhanced macrophage ABCA1-dependent cholesterol efflux. Methods: In this study, we wanted to test whether our LP-pXMoA5p delivery system is successful when utilizing cultured macrophage-like cells as the recipient cells for endothelial-cell-derived exosomes loaded with anti-miR-33a-5p. To test the atheroprotective efficacy of our LP-pXMoA5p delivery method, we measured miR-33a-5p expression, ABCA1 protein expression, and apoAI-mediated cholesterol efflux in recipient macrophage-like cells. Results: In our experiments, we observed that cultured macrophage-like cells incubated with anti-miR-33a-5p-filled exosomes exhibited high levels of cellular anti-miR-33a-5p, which resulted in decreased miR-33a-5p expression. Moreover, inhibition of miR-33a-5p within macrophage-like cells caused enhanced apoAI-mediated cholesterol efflux in these cells, which was likely the result of increased ABCA1 protein expression. Conclusions: Our findings reveal that LP-pXMoA5p appears capable of enhancing ABCA1-dependent cholesterol efflux within cultured macrophage-like cells, with this outcome potentially being due to macrophage-like cells internalizing anti-miR-33a-5p-loaded exosomes which are secreted by pro-inflammatory cultured immortalized mouse aortic endothelial cells (iMAECs), but we acknowledge this may not translate to similar effects in vivo.

  • Open Access

    Epithelial–Macrophage Crosstalk in Host Responses to Campylobacter jejuni Infection in Humans

    by Khaled Abdelaziz, Shreeya Sharma, Mostafa Naguib, Alexis Stamatikos

    Interactions between Campylobacter jejuni and host immune cells have been studied using various single-cell line models, such as macrophages and intestinal epithelial cells; however, these single-cell approaches do not fully capture the complexity of the host response. Investigating the interactions between these cell types offers a more comprehensive model for understanding Campylobacter–host dynamics. Therefore, this study aimed to investigate these interactions, specifically between intestinal epithelial cells and macrophages, using an in vitro model of C. jejuni infection. We examined whether soluble factors secreted from C. jejuni-infected HT-29 cells (human colorectal adenocarcinoma cells that express characteristics of mature intestinal cells) at 10 and 50 multiplicities of infection (MOI) influence RAW 264.7 macrophage activity, including nitric oxide (NO) production, migration, phagocytosis, bacterial killing, and the expression of cytokines (IL-6, IL-1β, TNF-α) and the chemokine CCL2. C. jejuni infection of HT-29 cells at 10 MOI induced significant IFN-γ production, a key macrophage activator. The treatment of macrophages with supernatants from HT-29 cells infected with C. jejuni significantly increased NO production, enhanced migration and phagocytic activity, and increased IL-6, TNF-α and CCL2 gene expression. However, no significant killing of phagocytosed C. jejuni was observed. On the other hand, supernatants from HT-29 cells infected with 50 MOI of C. jejuni suppressed NO production and macrophage phagocytosis, which may explain individual variations in the immune system’s ability to contain infection, potentially influenced by the infectious dose. These findings support the notion that Campylobacter can evade macrophage killing even under activated conditions. Further studies are needed to elucidate the molecular mechanisms by which Campylobacter survives within activated macrophages.

  • Open Access

    One Shock, Not One Cure: Electroporation Reveals Disease-Specific Constraints in Hepatocyte Gene Editing Therapy

    by Callie Clark, Menam Pokhrel, Benjamin Arthur, Pramita Suresh, Ilayda Ates, Justin Gibson, Abishek Dhungana, Ryan Mehlem, Andrew Boysia, Mugdha V. Padalkar, et al.

    We previously demonstrated lipid nanoparticle-mediated CRISPR-Cas9 gene editing to disrupt the gene encoding cytochrome P450 oxidoreductase (Cypor), combined with transient administration of acetaminophen (APAP), to repopulate the liver with healthy hepatocytes and rescue a phenylketonuria mouse model. This study aimed to investigate electroporation-mediated delivery of Cypor-targeting CRISPR-Cas9 ribonucleoproteins into wild-type hepatocytes, combined with liver engraftment under APAP treatment, as an in vivo selection approach in a mouse model of homozygous familial hypercholesterolemia (Ldlr−/−). Electroporation provides higher delivery efficiency compared to lipid nanoparticles. We observed engraftment levels up to 13% engraftment of electroporated Cypor-deficient hepatocytes with indels in the liver of Ldlr−/− mice after transient APAP administration, while negligible engraftment was observed in no-APAP controls (mean 9% and 2%, respectively, p = 0.0121). The engraftment of Cypor-deficient Ldlr+/+ hepatocytes was associated with reductions in LDL-cholesterol (18%) and triglycerides (52%) compared to the untransplanted control Ldlr−/− mice fed a Western diet for 5 weeks, but offered no protection from the development of diet-induced aortic root atherosclerosis or liver steatosis. While biochemical markers for liver damage normalized after discontinuation of APAP, we observed persistent lipid accumulation in the liver of Ldlr−/− mice grafted with Cypor-deficient Ldlr+/+ hepatocytes, likely stemming from the impact of Cypor deficiency on cholesterol clearance. Therefore, the combination of CRISPR-Cas9-mediated Cypor knockdown to induce clonal expansion of gene-edited hepatocytes using transient APAP administration is not a viable therapeutic strategy for familial hypercholesterolemia due to the essential role of Cypor in cholesterol metabolism. Unlike findings from phenylketonuria mouse model studies, the loss of Cypor function could not be compensated by unedited native hepatocytes in Ldlr−/− mice. Collectively, our results demonstrate that electroporation is a viable and informative approach for evaluating gene editing strategies for the treatment of inherited metabolic diseases that affect the liver. Our electroporation procedure revealed that a one-size-fits-all gene editing strategy may not be universally applicable for treating inherited metabolic liver disorders. Tailored gene editing and selection strategies may be needed for different liver disorders.


  • Open Access

    Ex Vivo Characterization of Peritoneal Macrophages from Novel ABCA1-LSL and ABCG1-LSL Mice for Macrophage-Specific ABC-Transporter Overexpression

    by Jing Echesabal-Chen, Lawrence Fernando, Ally Brawner, Achala Pokhrel, Kun Huang, Rhonda Reigers Powell, Terri Bruce, Jan Guz, Fu-Lei Tang, Alexander Awgulewitsch, et al.

    We aimed to characterize peritoneal macrophages from two novel mouse models that enable macrophage-specific overexpression of ABCA1 and ABCG1 via Cre recombinase. Since ABCA1/ABCG1 expression in macrophages is acknowledged to be anti-atherogenic, overexpression of these two transporters may result in a potent atheroprotective effect. However, there are no current animal models that permit overexpression of ABCA1/ABCG1 to precisely occur in macrophages. The purpose of this work was to use ex vivo strategies to characterize the peritoneal macrophages from two novel mouse models: ABCA1-LSL mice and ABCG1-LSL mice. Overexpression of ABCA1/ABCG1 in peritoneal macrophages is controlled by Cre recombinase, due to the LoxP-Stop-LoxP (LSL) system regulating ABC-transporter overexpression. In this study, we first characterized cells isolated from the peritoneal cavities of mice via immunofluorescent staining with macrophage markers CD11b and F4/80 to confirm that we were successful with peritoneal macrophage isolation. We next isolated peritoneal macrophages from ABCA1-LSL mice and ABCG1-LSL mice, and then we incubated these cells with gesicle particles containing Cre recombinase to measure ABC-transporter expression via immunoblotting and measure apoAI/HDL-mediated efflux using cholesterol efflux assays. In our experiments, we observed increases in ABCA1 protein expression and apoAI-mediated cholesterol efflux within ABCA1-LSL peritoneal macrophages, and increased ABCG1 protein expression and HDL-mediated cholesterol efflux in ABCG1-LSL peritoneal macrophages, when compared to corresponding control peritoneal macrophage groups. In conclusion, this report shows that ABCA1-LSL mice and ABCG1-LSL mice may possibly be utilized to cross with macrophage-specific Cre mice to study ABC-transporter overexpression precisely in macrophages, thereby providing valuable tools to dissect the impact of macrophage-specific ABC-transporter overexpression on atherogenesis.


  • Open Access

    Differential Expression of Key Immune Markers in the Intestinal Tract of Developing Chick Embryos

    by Shreeya Sharma, Mohammadali Alizadeh, Scott Pratt, Alexis Stamatikos, Khaled Abdelaziz

    Research on the immunological development of lymphoid organs in chicks has been extensive, yet a significant gap exists in our understanding of innate immunity during embryonic life within the intestinal tract. This study investigated the developmental trajectory of intestinal immunity in chick embryos by evaluating basal gene expression levels of key immune markers at embryonic days (ED) 14, 17, and 20. The results indicated variable expression levels of cytokines, antimicrobial peptides (AMPs), and Toll-like receptor (TLRs) genes throughout the intestinal tract. Most cytokines and chemokines exhibited elevated expression in the cecum, while AMPs, including avian-β-defensins (AvBDs) and cathelicidins (CATHs) genes, showed increased levels in the jejunum at ED20. The findings from the developmental trajectory analysis of these genes revealed elevated expression levels of cytokines, including interferon (IFN)-γ, interleukin (IL)-6, IL-13, and transforming-growth factor (TGF)-β in the cecum at ED20. However, no consistent patterns were observed for AvBDs, CATHs, and TLRs, as their expression varied across different developmental stages of the chick embryo. These findings significantly contribute to our understanding of intestinal immune system development in chick embryos and provide a foundation for further research aimed at enhancing immune capabilities, especially in segments with lower expression levels of immunomodulatory genes.


  • Open Access

    Inhibiting MiR-33a-3p Expression Fails to Enhance ApoAI-Mediated Cholesterol Efflux in Pro-Inflammatory Endothelial Cells

    by Kun Huang, Achala Pokhrel, Jing Echesabal-Chen, Justin Scott, Terri Bruce, Hanjoong Jo, Alexis Stamatikos

    Background and Objectives: Atherosclerosis is an inflammatory condition that results in cholesterol accumulating within vessel wall cells. Atherosclerotic cardiovascular disease is the leading cause of mortality worldwide due to this disease being a major contributor to myocardial infarctions and cerebrovascular accidents. Research suggests that cholesterol accumulation occurring precisely within arterial endothelial cells triggers atherogenesis and exacerbates atherosclerosis. Furthermore, inflamed endothelium acts as a catalyst for atherosclerotic development. Therefore, enhancing cholesterol removal specifically in pro-inflammatory endothelial cells may be a potential treatment option for atherosclerosis. While we have previously shown that inhibiting the microRNA guide strand miR-33a-5p within pro-inflammatory endothelial cells increases both ABCA1 expression and apoAI-mediated cholesterol efflux, it is unknown whether inhibiting the miR-33a-3p passenger strand in pro-inflammatory endothelial cells causes similar atheroprotective effects. In this study, this is what we aimed to test. Materials and Methods: We used plasmid transfection to knockdown miR-33a-3p expression within cultured pro-inflammatory immortalized mouse aortic endothelial cells (iMAECs). We compared ABCA1 expression and apoAI-mediated cholesterol efflux within these cells to cultured pro-inflammatory iMAECs transfected with a control plasmid. Results: The knockdown of miR-33a-3p expression within pro-inflammatory iMAECs resulted in a significant increase in ABCA1 mRNA expression. However, the inhibition of miR-33a-3p did not significantly increase ABCA1 protein expression within pro-inflammatory iMAECs. Moreover, we failed to detect a significant increase in apoAI-mediated cholesterol efflux within pro-inflammatory iMAECs from miR-33a-3p knockdown. Conclusions: Our results indicative that the knockdown of miR-33a-3p alone does not enhance ABCA1-dependent cholesterol efflux within pro-inflammatory endothelial cells. To gain any atheroprotective benefit from inhibiting miR-33a-3p within pro-inflammatory endothelium, additional anti-atherogenic strategies would likely be needed in unison.


  • Open Access

    Exosome-Mediated Transfer of X-Motif-Tagged Anti-MiR-33a-5p Antagomirs to the Medial Cells of Transduced Rabbit Carotid Arteries

    by Goren Saenz-Pipaon, Bradley K. Wacker, Lianxiang Bi, Alexis Stamatikos, David A. Dichek

    Atherosclerosis is caused by the accumulation of cholesterol within intimal smooth muscle cells (SMCs) and macrophages. However, the transporter ATP-binding cassette subfamily A, member 1 (ABCA1), can remove cholesterol from these intimal, cells reducing atherosclerosis. Antagomir-mediated inhibition of miR-33a-5p, a microRNA that represses ABCA1 translation, promotes ABCA1-dependent cholesterol efflux and may impede atherosclerosis development. In our previous work, transducing cultured endothelial cells (ECs) with a helper-dependent adenoviral vector (HDAd) that expresses X-motif-tagged anti-miR-33a-5p enhanced antagomir packaging into EC-derived exosomes, which delivered the antagomir to cultured SMCs and macrophages. In this present study, we tested whether in vivo transduction of rabbit carotid artery endothelium can deliver an X-motif-tagged anti-miR-33a-5p to subendothelial cells. Rabbit carotid endothelial cells were transduced in vivo with an HDAd expressing anti-miR-33a-5p either with or without the X-motif (n = 11 arteries per vector). Contralateral carotids received HDAd that express scrambled oligonucleotides. Three days after transduction, the antagomir—without the X-motif—was detected in the intima but not in the media of transduced carotids (p = 0.062). The X-motif antagomir was detected in 82% of the intimal extracts (9 out of 11 carotids) and 27% of medial samples (3 out of 11 carotids, p = 0.031). However, the X-motif did not significantly enhance antagomir delivery to the media (p = 0.214 vs. non-X-motif antagomir). Expression of the antagomirs—with and without the X-motif—was sub-stoichiometric in ECs and SMCs. No antagomir-related changes in miR-33a-5p or ABCA1 expressions were detected. Despite its potential as a therapeutic strategy, our exosome-targeted gene transfer system requires further improvements to enhance antagomir expression and delivery to the subendothelial cells.


  • Open Access

    Cholesterol Efflux Decreases TLR4-Target Gene Expression in Cultured Macrophages Exposed to T. brucei Ghosts

    by Lawrence Fernando, Jing Echesabal-Chen, Murphy Miller, Rhonda Reigers Powell, Terri Bruce, Apurba Paul, Nava Poudyal, Joshua Saliutama, Kristina Parman, Kimberly S. Paul, et al.

    Trypanosoma brucei causes African trypanosomiasis in humans. Infection with T. brucei elicits a potent pro-inflammatory immune response within infected human hosts, and this response is thought to at least be partially due to Toll-like receptor (TLR) activation. In response to stimulation by lipopolysaccharide and other pathogen antigens, TLR4 translocates to lipid rafts, which induces the expression of pro-inflammatory genes. However, cholesterol efflux is acknowledged as anti-inflammatory due to promoting lipid raft disruption. In this study, we wanted to assess the impact of T. brucei “ghosts”, which are non-viable T. brucei essentially devoid of intracellular contents, in stimulating macrophage TLR4 translocation to lipid rafts, and whether promoting cholesterol efflux in macrophages incubated with T. brucei ghosts attenuates TLR4-target gene expression. When cultured macrophages were exposed to T. brucei ghosts, we observed an increase in lipid raft TLR4 protein content, which suggests certain surface molecules of T. brucei serve as ligands for TLR4. However, pretreating macrophages with cholesterol acceptors before T. brucei ghost exposure decreased lipid raft TLR4 protein content and the expression of pro-inflammatory TLR4-target genes. Taken together, these results imply that macrophage cholesterol efflux weakens pro-inflammatory responses which occur from T. brucei infection via increasing macrophage lipid raft disruption.


  • Open Access

    Inhibition of miR-33a-5p in Macrophage-like Cells In Vitro Promotes apoAI-Mediated Cholesterol Efflux

    by Olanrewaju Oladosu, Emma Chin, Christian Barksdale, Rhonda R. Powell, Terri Bruce, Alexis Stamatikos

    Atherosclerosis is caused by cholesterol accumulation within arteries. The intima is where atherosclerotic plaque accumulates and where lipid-laden foam cells reside. Intimal foam cells comprise of both monocyte-derived macrophages and macrophage-like cells (MLC) of vascular smooth muscle cell (VSMC) origin. Foam cells can remove cholesterol via apoAI-mediated cholesterol efflux and this process is regulated by the transporter ABCA1. The microRNA miR-33a-5p is thought to be atherogenic via silencing ABCA1 which promotes cholesterol retention and data has shown inhibiting miR-33a-5p in macrophages may be atheroprotective via enhancing apoAI-mediated cholesterol efflux. However, it is not entirely elucidated whether precisely inhibiting miR-33a-5p in MLC also increases ABCA1-dependent cholesterol efflux. Therefore, the purpose of this work is to test the hypothesis that inhibition of miR-33a-5p in cultured MLC enhances apoAI-mediated cholesterol efflux. In our study, we utilized the VSMC line MOVAS cells in our experiments, and cholesterol-loaded MOVAS cells to convert this cell line into MLC. Inhibition of miR-33a-5p was accomplished by transducing cells with a lentivirus that expresses an antagomiR directed at miR-33a-5p. Expression of miR-33a-5p was analyzed by qRT-PCR, ABCA1 protein expression was assessed via immunoblotting, and apoAI-mediated cholesterol efflux was measured using cholesterol efflux assays. In our results, we demonstrated that lentiviral vector-mediated knockdown of miR-33a-5p resulted in decreasing expression of this microRNA in cultured MLC. Moreover, reduction of miR-33a-5p in cultured MLC resulted in de-repression of ABCA1 expression, which caused ABCA1 protein upregulation in cultured MLC. Additionally, this increase in ABCA1 protein expression resulted in enhancing ABCA1-dependent cholesterol efflux through increasing apoAI-mediated cholesterol efflux in cultured MLC. From these findings, we conclude that inhibiting miR-33a-5p in MLC may protect against atherosclerosis by promoting ABCA1-dependent cholesterol efflux.